Medically reviewed by Kayla Girgen, RD Persistent sleep struggles, especially due to insomnia, can be a major disruption to ...
Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...
As Georgia navigates a widespread opioid addiction crisis, researchers in Kennesaw State University's Wellstar School of Nursing (WSON) are leveraging a $1.2 million grant to train budding nurses in ...
An online-based mindfulness treatment program significantly reduced opioid craving among participants with opioid use disorder results from a randomized clinical trial published in JAMA Network Open ...
Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
Rutgers Health, in partnership with the New Jersey Department of Labor and Workforce Development (NJDOL), has launched the ...
Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...
“Nurses Learning About Opioid Use Disorder,” or Nurses LOUD. The grant was made possible following a $636 million settlement reached with three pharmaceutical companies for their complicity in ...
DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), is developing ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
where the cost savings would be primarily due to averting cases of opioid use disorder. The FDA's approval was based on data from two late-stage trials, which showed that the drug significantly ...